Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions

References

• Page C, Humphrey P. Sir David Jack: an extraordinary drug discoverer and developer. Br J Clin Pharmacol. 2013;75(5):1213–1218.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Breckenridge A. David jack (1924–2011) who revolutionised the treatment of asthma. Thorax. [ internet] 2012 [cited 2021 Jan 10];67(3):266–267.
   Web of Science ®Google Scholar
• Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15(6):326–331.
   PubMedGoogle Scholar
• Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20–41.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Buttini F, Usmani OS. 100 Years of Drug Delivery to the Lungs. Handb Exp Pharmacol. 2019;260:143–159.
   PubMedGoogle Scholar
• Biddiscombe MF, Usmani OS. Is there room for further innovation in inhaled therapy for airways disease? Breathe (Sheff). 2018;14(3):216–224.
   PubMedGoogle Scholar
• Global strategy for asthma management and prevention GINA. (2021 update). [cited 2021 Sep 10]. Available from: www.ginasthma.org
   Google Scholar
• Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med. 2016;26(1):16068.
   PubMedGoogle Scholar
• Duse M, Santamaria F, Verga MC, et al. Inter-society consensus for the use of inhaled corticosteroids in infants, children and adolescents with airway diseases. Ital J Pediatr. 2021 Apr 21;47(1):97.
   PubMed Web of Science ®Google Scholar
• Lai K, Chen R, Peng W, et al. Non-asthmatic eosinophilic bronchitis and its relationship with asthma. Pulm Pharmacol Ther. 2017;47:66–71.
   PubMed Web of Science ®Google Scholar
• Holt S, Suder A, Weatherall M, et al. Dose–response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323(7307):253–256.
   PubMedGoogle Scholar
• Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368:780–793.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601.
   PubMed Web of Science ®Google Scholar
• Global Strategy for Diagnosis, Management and Prevention of COPD. The global initiative for chronic obstructive lung diseases (GOLD). 2020 report.[cited 2020 Dec 20]. Available from: https://goldcopd.org/gold-reports/
   Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508–1516.
   PubMed Web of Science ®Google Scholar
• Skoner DP. Inhaled corticosteroids: effects on growth and bone health. Ann Allergy Asthma Immunol. 2016;117(6):595–600.
   PubMed Web of Science ®Google Scholar
• Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100(8):1307–1317.
   PubMed Web of Science ®Google Scholar
• Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8(1):59–65.
   PubMedGoogle Scholar
• Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126(1):213–219.
   PubMed Web of Science ®Google Scholar
• Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56(10):944–948.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Lahdensuo A, Moilanen E, et al. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res. 2004;5(1):17.
   PubMedGoogle Scholar
• Masoli M, Holt S, Weatherall M, et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23(4):552–558.
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall J, Jones P. Beclomethasone at different doses for chronic asthma (review). Cochrane Database Syst Rev. 2001;1999(1):CD002879.
   PubMedGoogle Scholar
• Hart K, Weatherall M, Shirtcliffe P, et al. Frequency of dosing and comparative doses of mometasone furoate: a meta-analysis. Respirology. 2009 Nov;14(8):1166–1172.
   PubMed Web of Science ®Google Scholar
• Anderson WJ, Short PM, Jabbal S, et al. Inhaled corticosteroid dose response in asthma: should we measure inflammation? Ann Allergy Asthma Immunol. 2017;118(2):179–185.
   PubMed Web of Science ®Google Scholar
• O’Sullivan S, Cormican L, Murphy M, et al. Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma. Chest. 2002 Dec;122(6):1966–1972.
   PubMed Web of Science ®Google Scholar
• Heffler E, Madeira LNG, Ferrando M, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):776–781.
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Wojciechowski P, Dziewonska M, et al. Adrenal suppression by inhaled corticosteroids in patients with asthma: a systematic review and quantitative analysis. Allergy Asthma Proc. 2016;37(1):9–17.
   PubMed Web of Science ®Google Scholar
• Chiu KL, Lee CC, Chen CY. Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Sci Rep. 2021 Jan 12;11(1):724.
   PubMed Web of Science ®Google Scholar
• Weatherall M, Clay J, James K, et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009 Sep;14(7):983–990.
   PubMed Web of Science ®Google Scholar
• Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008 Sep;38(9):1451–1458.
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006.
   PubMed Web of Science ®Google Scholar
• Ye Q, Xo H, D’Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3(1):1–18. A useful article describing different strategies that strike a balance between safety and efficacy of ICS therapy
   Google Scholar
• Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012 Sep 6;367(10):904–912.
   PubMed Web of Science ®Google Scholar
• Beasley R, Harper J, Bird G, et al. Inhaled corticosteroid therapy in adult asthma. time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019 Jun 15;199(12):1471–1477.
   PubMed Web of Science ®Google Scholar
• Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. J Pharm Sci. 2016;105(9):2509–2514.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rinaldi B, Calzetta L, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019;58:101828.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20(1):23–35.
   PubMed Web of Science ®Google Scholar
• Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100(3):375–384.
   PubMed Web of Science ®Google Scholar
• Pedersen SE, Prasad N, Goehring UM, et al. Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day. J Asthma Allergy. 2017;10:35–46.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60(3):330–337.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Cheung D, Lapa E, et al. Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma. Pulm Pharmacol Ther. 2008;21(3):489–498.
   PubMed Web of Science ®Google Scholar
• Kupryś-Lipińska I, Kuna P. Role of ciclesonide in asthma therapy. Pneumonol Alergol Pol. 2008;76(1):37–43. Polish
   PubMedGoogle Scholar
• Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45(2):146–152.
   PubMed Web of Science ®Google Scholar
• Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 2005;99(10):1275–1285.
   PubMed Web of Science ®Google Scholar
• Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev. 2008;2:CD007031. 10.1002/14651858.CD007031
   PubMed Web of Science ®Google Scholar
• Derom E, Louis R, Tiesler C, et al. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J. 2009 Jun;33(6):1277–1286.
   PubMed Web of Science ®Google Scholar
• Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database Syst Rev. 2014;7:CD009471. 10.1002/14651858.CD009471.pub2
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e199–205.
   PubMed Web of Science ®Google Scholar
• Kapadia CR, Nebesio TD, Myers SE, et al., Endocrine effects of inhaled corticosteroids in children. JAMA Pediatr. 2016;170(2):163–170.
   PubMed Web of Science ®Google Scholar
• Gelfand EW, Georgitis JW, Noonan M, et al. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr. 2006;148(3):377–383.
   PubMed Web of Science ®Google Scholar
• Von Berg A, Engelstätter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol. 2007;18(5):391–400.
   PubMed Web of Science ®Google Scholar
• Liddell BS, Oberlin JM, Hsu DP. Inhaled corticosteroid related adrenal suppression detected by poor growth and reversed with ciclesonide. J Asthma. 2017;54(1):99–104.
   PubMed Web of Science ®Google Scholar
• Heller MK, Laks J, Kovesi TA, et al. Reversal of adrenal suppression with ciclesonide. J Asthma. 2010;47(3):337–339.
   PubMed Web of Science ®Google Scholar
• Cavkaytar O, Vuralli D, Arik Yilmaz E, et al. Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use. Eur J Pediatr. 2015;174(11):1421–1431.
   PubMed Web of Science ®Google Scholar
• Lapi F, Kezouh A, Suissa S, et al. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J. 2013;42(1):79–86.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537.
   PubMed Web of Science ®Google Scholar
• He Y, Yi W, Suino-Powell K, et al., Structures and mechanism for the design of highly potent glucocorticoids. Cell Res. 2014;24(6):713–726.
   PubMed Web of Science ®Google Scholar
• Yang D, Wang J, Bunjhoo H, et al. Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. Asian Pac J Allergy Immunol. 2013;31(1):26–35.
   PubMed Web of Science ®Google Scholar
• Navaratnam P, Friedman HS, Urdaneta E. Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. Value Health. 2011;14(2):339–346.
   PubMed Web of Science ®Google Scholar
• Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Navaratnam P, McLaughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J Asthma. 2010;47(9):994–1000.
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2000;106(5). 10.1067/mai.2000.110798.
   Web of Science ®Google Scholar
• Karpel JP, Nayak A, Lumry W, et al. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med. 2007;101(3):628–637.
   PubMed Web of Science ®Google Scholar
• Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med. 2001 Aug 15;164(4):569–574.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9(1):73.
   PubMedGoogle Scholar
• D’Urzo A. Mometasone furoate dry-powder inhaler for the control of persistent asthma. Expert Opin Pharmacother. 2007;8(16):2871–2884.
   PubMed Web of Science ®Google Scholar
• Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med. 2004;170(9):960–966.
   PubMed Web of Science ®Google Scholar
• Milgrom H. Mometasone furoate in children with mild to moderate persistent asthma: a review of the evidence. Paediatr Drugs. 2010;12(4):213–221.
   PubMedGoogle Scholar
• Koner DP, Meltzer EO, Milgrom H, et al. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma. 2011;48(8):848–859.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Fixed-dose combination inhalers. Handb Exp Pharmacol. 2017;237:117–129.
   PubMedGoogle Scholar
• van Zyl-smit RN, Krüll M, Gessner C, et al. PALLADIUM trial investigators. once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–999.
   PubMed Web of Science ®Google Scholar
• Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: phase III randomised QUARTZ study findings. Respir Med. 2020;161:105809.
   PubMed Web of Science ®Google Scholar
• Enerzair® Breezhaler® 114 micrograms/46 micrograms/136 micrograms inhalation powder, hard capsules Indacaterol acetate/glycopyrronium bromide/mometasone furoate. Summary of product characteristics. [internet].[ [internet] 2021 20 Feb]. [internet]: https://www.medicines.org.uk/emc/product/11886/smpc#gref.
   Google Scholar
• Atectura® Breezhaler® 125 micrograms/62.5 micrograms,125 micrograms/127.5 micrograms,125 micrograms/260 micrograms inhalation powder, hard capsules. Indacaterol acetate/mometasone furoate. Summary of product characteristics .[internet].[cited 2021 Feb 20]. Available from: https://www.medicines.org.uk/emc/product/11885/smpc#gref.
   Google Scholar
• Asmanex® twisthaler® 400 micrograms inhalation powder. mometasone furoate. Summary of product characteristics .[internet].[cited 2021 Feb 20]. Available from: https://www.medicines.org.uk/emc/product/6753/smpc#gref.
   Google Scholar
• Buhl R, Tanase AM, Hosoe M, et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via breezhaler® or twisthaler® in patients with asthma. Pulm Pharmacol Ther. 2020;62:101919.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kirsten AM, Tanase AM, et al. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a phase II randomized, double-blind 12-week study. Int J Chron Obstruct Pulmon Dis. 2018;13:3923–3936.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Drugs Today (Barc). 2015;51(8):469–478.
   PubMed Web of Science ®Google Scholar
• Biggadike K. Fluticasone furoate/fluticasone propionate - different drugs with different properties. Clin Respir J. 2011;5(3):183–184.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380.
   PubMed Web of Science ®Google Scholar
• Villa E, Magnoni MS, Micheli D, et al. A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother. 2011;12(13):2107–2117.
   PubMed Web of Science ®Google Scholar
• Jacques L, Bakerly ND, New JP, et al., Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the salford lung study. J Asthma. 2019;56(7):748–757.
   PubMed Web of Science ®Google Scholar
• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670(1):244–251.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Jacques L, Goldfrad C, et al. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov;17(1):157.
   PubMedGoogle Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012 May;106(5):642–650.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012 Jan;67(1):35–41.
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483–493.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Chan R, and Kuo CRW. End-point selection to determine the airway-systemic ratio of inhaled corticosteroids in asthma. Br J Clin Pharmacol. 2021;87(2) 2401–2402.
   PubMedGoogle Scholar
• Woodcock A, Lötvall J, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med. 2014;14(1):113.
   PubMedGoogle Scholar
• Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012;109(5):353–358.e4.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res. 2011;12(1):132.
   PubMedGoogle Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67(1):35–41.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108(1):41–49.
   PubMed Web of Science ®Google Scholar
• Morice AH, Hart SP. Increased propensity for pneumonia with fluticasone in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(9):1229–1230.
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir Med. 2017;131:27–34.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Averell C, Parker ED, et al. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/Long-acting β-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(5):1488–1496.e7.
   PubMed Web of Science ®Google Scholar
• Parimi M, Svedsater H, Ann Q, et al. Persistence and adherence to ICS/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916–2931.
   PubMed Web of Science ®Google Scholar
• Averell CM, Stanford RH, Laliberté F, et al. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Averell CM, Johnson PT, et al. Adherence and usage patterns of inhaled corticosteroids-long-acting beta-agonists by using inhaler-monitoring technology. Allergy Asthma Proc. 2020;41(4):256–264.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Shiobara T, Arai R, et al. Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: relvar ellipta for real asthma control study (RERACS study). J Thorac Dis. 2020;12(5):1877–1883.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84.
   PubMed Web of Science ®Google Scholar
• Price D, Bosnic-Anticevich S, and BriggsA, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107(1):37–46.
   PubMed Web of Science ®Google Scholar
• Aydemir Y. Assessment of the factors affecting the failure to use inhaler devices before and after training. Respir Med. 2015;109(4):451–458.
   PubMed Web of Science ®Google Scholar
• Rootmensen GN, van Keimpema AR, Jansen HM, et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23(5):323–328.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Gruppo educazionale associazione italiana pneumologi ospedalieri. inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938.
   PubMed Web of Science ®Google Scholar
• Fernández Tena A, Casan Clarà P. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48(7):240–246.
   PubMed Web of Science ®Google Scholar
• Glover W, Chan HK, Eberl S, et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm. 2008 Feb 12;349(1–2):314–322.
   PubMedGoogle Scholar
• Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med. 2001;14(Suppl 1):S19–26.
   PubMedGoogle Scholar
• Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011 Mar 19;377(9770):1032–1045.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled Corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–540.
   PubMedGoogle Scholar
• Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000 Dec;106(6):1209–1226.
   PubMed Web of Science ®Google Scholar
• Kardas P, Lewek P, Strzondała M. Adherence to treatment in asthma and COPD patients in their doctors’ assessment. Pneumonol Alergol Pol. 2015;83(6):436–444.
   PubMedGoogle Scholar
• Darbà J, Ramírez G, Sicras A, et al. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015 Oct 29;10:2335–2345.
   PubMed Web of Science ®Google Scholar
• Kardas G, Panek M, Kuna P, et al. Primary non-adherence to inhaled medications measured with e-prescription data from Poland. Clin Transl Allergy. 2020; 10(39). 10.1186/s13601-020-00346-7
   PubMedGoogle Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011 Mar;105(3):435–441.
   PubMed Web of Science ®Google Scholar
• van Boven JFM, Cushen B, Sulaiman I, et al. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ Prim Care Respir Med. 2018;28(1):24.
   PubMed Web of Science ®Google Scholar
• Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD–an assessment of inhaler technique and patient preferences. Respir Med. 2014;108(7):968–975.
   PubMed Web of Science ®Google Scholar
• Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med. 2020 Aug 20;20(1):222.
   PubMed Web of Science ®Google Scholar
• Ninane V, Vandevoorde J, Cataldo D, et al. New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109(11):1430–1438.
   PubMed Web of Science ®Google Scholar
• Principe S, Battaglia S, Benfante A, et al. Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma? J Asthma. 2020; 1–16. 10.1080/02770903.2020.1850766.
   Web of Science ®Google Scholar
• Roche N, Dekhuijzen PN. The evolution of pressurized metered-dose inhalers from early to modern devices. J Aerosol Med Pulm Drug Deliv. 2016;29(4):311–327.
   PubMed Web of Science ®Google Scholar
• Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104(6):1215–1222.
   PubMed Web of Science ®Google Scholar
• Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther. 2003;25(3):776–798.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Apr;14(4):533–541.
   PubMed Web of Science ®Google Scholar
• Deeks ED, Lyseng-Williamson KA. K-haler® breath-triggered inhaler: a profile of the properties of the device. Drugs Ther Perspect. 2019;35(7):315–320.
   Google Scholar
• Morais-Almeida M, Pité H, Cardoso J, et al. Asthma management with breath-triggered inhalers: innovation through design. Asthma Res Pract. 2020;6(1):4.
   PubMedGoogle Scholar
• Kupczyk M, Majak P, Kuna P, et al. A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study. Respir Med. 2021;176:106274.
   PubMed Web of Science ®Google Scholar
• Volerman A, Balachandran U, Siros M, et al. Mask use with spacers/valved holding chambers and metered dose inhalers among children with asthma. Ann Am Thorac Soc. 2021;18(1):17–22.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Barreto C, van Boven JFM, et al. Spacers and valved holding chambers-the risk of switching to different chambers. J Allergy Clin Immunol Pract. 2020 May;8(5):1569–1573.
   PubMed Web of Science ®Google Scholar
• Panigone S, Sandri F, Ferri R, et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res. 2020;7(1):e000571.
   PubMed Web of Science ®Google Scholar
• Janson C, Henderson R, Löfdahl M, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020 Jan;75(1):82–84.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Investing in a sustainable future for patients with respiratory disease. [internet].[cited 2021 Aug 1] Available from: https://www.astrazeneca.com/media-centre/articles/2020/investing-in-a-sustainable-future-for-patients-with-respiratory-disease.html
   Google Scholar
• Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009;18(4):243–249.
   PubMedGoogle Scholar
• Longest PW, Tian G, Walenga RL, et al. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharm Res. 2012;29(6):1670–1688.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Poli G, Herpich C, et al. Lung deposition of the dry powder fixed combination beclometasone dipropionate plus formoterol fumarate using NEXThaler® device in healthy subjects, asthmatic patients, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2018;31(5):269–280.
   PubMed Web of Science ®Google Scholar
• Buttini F, Brambilla G, Copelli D, et al. Effect of flow rate on in vitro aerodynamic performance of NEXThaler(®) in comparison with diskus(®) and turbohaler(®) dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2016;29(2):167–178.
   PubMed Web of Science ®Google Scholar
• Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014;11(9):1497–1506.
   PubMed Web of Science ®Google Scholar
• Farkas Á, Lewis D, Church T, et al. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhaler. Int J Pharm. 2017 25; 533(1):225–235.
   PubMedGoogle Scholar
• Emeryk A, Pirożyński M. New dry powder inhalers. Pneumonol Alergol Pol. 2015;83(1):83–87. Polish
   PubMedGoogle Scholar
• Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020 Feb;17(2):133–144.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Gillespie M, Song S, et al. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids. J Asthma. 2017;54(1):89–98.
   PubMed Web of Science ®Google Scholar
• Mansfield L, Yiu G, and Sakov A, et al.A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. Allergy Asthma Proc. 2017 38 (4) 264–276 .
   PubMed Web of Science ®Google Scholar
• Joyce M, McGrath JA, Mac Giolla Eain M, et al. Nebuliser type influences both patient-derived bioaerosol emissions and ventilation parameters during mechanical ventilation. Pharmaceutics 2021;13(2):199.
   PubMed Web of Science ®Google Scholar
• Pritchard JN, Hatley RH, Denyer J, et al. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv. 2018;9(2):121–136.
   PubMed Web of Science ®Google Scholar
• McCarthy SD, González HE, Higgins BD. Future trends in nebulized therapies for pulmonary disease. J Pers Med. 2020;10(2):37.
   PubMed Web of Science ®Google Scholar
• Moody GB, Luckett PM, Shockley CM, et al. Clinical efficacy of vibrating mesh and jet nebulizers with different interfaces in pediatric subjects with asthma. Respir Care. 2020;65(10):1451–1463.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646.
   PubMed Web of Science ®Google Scholar
• Dalby RN, Eicher J, Zierenberg B. Development of respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–155.
   PubMedGoogle Scholar
• Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–1577.
   PubMed Web of Science ®Google Scholar
• Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960–964.
   PubMed Web of Science ®Google Scholar
• Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by respimat soft mist inhaler compared to deposition by metered dose inhaler or by turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–272.
   PubMedGoogle Scholar
• Wood CC, van Toor B, Hasselbarth V, et al. Improved efficiency of pulmonary delivery of budesonide with Respimat® Soft Mist™ inhaler compared with turbohaler or pMDI. J Allergy Clin Immun. 2006;117(2):S82–S82.
   Web of Science ®Google Scholar
• Hodder R, Reese PR, Slaton T. Asthma patients prefer respimat soft mist inhaler to turbuhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:225–232.
   PubMedGoogle Scholar
• Taube C, Bayer V, Zehendner CM, et al. Assessment of patient experiences with Respimat® in everyday clinical practice. Pulm Ther. 2020;6(2):371–380.
   PubMedGoogle Scholar
• Crisafulli E, Pisi R, Aiello M, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017;93(1):32–41.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Singh D, Spinola M, et al. The prevalence of small airways disease in adult asthma: a systematic literature review. Respir Med. 2016;116:19–27.
   PubMed Web of Science ®Google Scholar
• Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009;124(6 Suppl):S88–93.
   PubMed Web of Science ®Google Scholar
• Nave R, Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids. Int J Gen Med. 2013;6:99–107.
   PubMedGoogle Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–148.
   PubMed Web of Science ®Google Scholar
• Sonnappa S, McQueen B, Postma DS, et al., Extrafine versus fine inhaled corticosteroids in relation to asthma control: a systematic review and meta-analysis of observational real-life studies. J Allergy Clin Immunol Pract. 2018;6(3):907–915.e7.
   PubMed Web of Science ®Google Scholar
• Davies RJ, Stampone P, O’Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med. 1998;92:23–31. W.B. Saunders Ltd
   PubMed Web of Science ®Google Scholar
• Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest. 1999 Feb;115(2):343–351.
   PubMed Web of Science ®Google Scholar
• van der Molen T, Postma DS, Martin RJ, et al. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med. 2016 May 17;16(1):80.
   PubMedGoogle Scholar
• Vance D, Alnouri G, Valentino W, et al. Effects of particle size of inhaled corticosteroid on the voice. J Voice. 2021 May;35(3):455–457.
   PubMed Web of Science ®Google Scholar
• Thompson PJ, Davies RJ, Young WF, et al. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med. 1998 Jun;92(Suppl):A:33–9.
   PubMedGoogle Scholar
• Chen X, Kang Y, Wang L, et al. Extrafine HFA-beclomethasone dipropionate versus budesonide for asthma: a meta-analysis. Int J Clin Exp Med. 2015 Jan 15;8(1):212–221.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295–304.
   PubMed Web of Science ®Google Scholar
• Pirina P, Foschino Barbaro MP, Paleari D, et al. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respir Med. 2018;143:74–81.
   PubMed Web of Science ®Google Scholar
• Sonnappa S, Martin R, Israel E, et al., Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017;12(6):e0178112.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park YH, Kang DR, et al. Risk of pneumonia associated with inhaled corticosteroid in patients with chronic obstructive pulmonary disease: a Korean population-based study. Int J COPD. [ [Internet]] 2020 [cited 2021 Feb 14];15:3397–3406.
   Google Scholar
• European Medical Agency: EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease. Review finds no differences between products in risk of pneumonia. 2016. [internet].[cited 2021 Aug 2] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/04/news_detail_002521.jsp&mid=WC0b01ac058004d5c1.
   Google Scholar
• He Y, Shi J, Yi W, et al. Discovery of a highly potent glucocorticoid for asthma treatment. Cell Discov. 2015;1(1):15035.
   PubMedGoogle Scholar
• He Y, Shi J, Nguyen QT, et al. Development of highly potent glucocorticoids for steroid-resistant severe asthma. Proc Natl Acad Sci U S A. 2019;116(14):6932–6937.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Puxeddu E, et al. Experimental glucocorticoid receptor agonists for the treatment of asthma: a systematic review. J Exp Pharmacol. 2020;12:233–254.
   PubMedGoogle Scholar
• Brown MN, Fuhr R, Beier J, et al. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial. Respir Res. 2019;20(1):37.
   PubMedGoogle Scholar
• Gauvreau GM, Boulet LP, Leigh R, et al. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015;191(2):161–167.
   PubMed Web of Science ®Google Scholar
• Kuna P, Aurivillius M, Jorup C, et al. Efficacy and tolerability of an inhaled selective glucocorticoid receptor modulator - AZD5423 - in chronic obstructive pulmonary disease patients: phase II study results. Basic Clin Pharmacol Toxicol. 2017;121(4):279–289.
   PubMed Web of Science ®Google Scholar
• Li X, Vogt FG, Hayes D Jr, et al. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers. J Pharm Sci. 2014;103(9):2937–2949.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Mallory EK, Malapit M, et al. Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols. RSC Adv. 2020;10(68):41846–41856.
   PubMed Web of Science ®Google Scholar
• Rudokas M, Najlah M, Alhnan MA, et al. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25(Suppl2):60–72.
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–612.
   PubMed Web of Science ®Google Scholar
• Lühder F, Reichardt HM. Novel drug delivery systems tailored for improved administration of glucocorticoids. Int J Mol Sci. 2017;18(9):1836.
   PubMed Web of Science ®Google Scholar
• Chan AH, Harrison J, Black PN, et al. Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):335–49.e1-5.
   Web of Science ®Google Scholar
• Chrystyn H, Audibert R, Keller M, et al. Real-life inhaler adherence and technique: time to get smarter! Respir Med. 2019;158:24–32.
   PubMed Web of Science ®Google Scholar
• Moon C, Smyth HDC, Watts AB, et al., Delivery technologies for orally inhaled products: an update. AAPS PharmSciTech. 2019;20(3):117.
   PubMed Web of Science ®Google Scholar
• Makhecha S, Chan A, Pearce C, et al. Novel electronic adherence monitoring devices in children with asthma: a mixed-methods study. BMJ Open Respir Res. 2020;7(1):e000589.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1):1701126.
   PubMed Web of Science ®Google Scholar
• Sumino K, Locke ER, Magzamen S, et al. Use of a remote inhaler monitoring device to measure change in inhaler use with chronic obstructive pulmonary disease exacerbations. J Aerosol Med Pulm Drug Deliv. 2018;31(3):191–198.
   PubMed Web of Science ®Google Scholar
• Patel M, Pilcher J, Reddel HK, et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy. 2013;43(10):1144–1151.
   PubMed Web of Science ®Google Scholar
• Sorino C, Negri S, Spanevello A, et al. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–18.
   PubMed Web of Science ®Google Scholar
• Black PN, Lawrence BJ, Goh KH, et al. Differences in the potencies of inhaled steroids are not reflected in the doses prescribed in primary care in New Zealand. Eur J Clin Pharmacol. 2000 Aug;56(5):431–435.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887.
   PubMed Web of Science ®Google Scholar
• Larsson K, Kankaanranta H, Janson C, et al. Bringing asthma care into the twenty-first century. NPJ Prim Care Respir Med. 2020;30(1):25.
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928.
   PubMed Web of Science ®Google Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019 May 23;380(21):2020–2030.
   PubMed Web of Science ®Google Scholar
• Bloom CI, de Preux L, Sheikh A, et al. Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: a population-based observational study. PLoS Med. 2020 Jul 21;17(7):e1003145.
   PubMed Web of Science ®Google Scholar
• Stryczek K, Lea C, Gillespie C, et al. De-implementing inhaled corticosteroids to improve care and safety in copd treatment: primary care providers’ perspectives. J Gen Intern Med. 2020 Jan;35(1):51–56.
   PubMed Web of Science ®Google Scholar
• Bloom CI, Ramsey H, Alter M, et al. Qualitative study of practices and challenges of stepping down asthma medication in primary care across the UK. J Asthma Allergy. 2020 Oct;6(13):429–437.
   Google Scholar